Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults

Inclusion Criteria: Healthy adults; age greater than 18 years, less than or equal to 40 years HIV-1 negative as documented by negative ELISA and negative Western blot analysis within 30 days prior to immunization Normal history and physical exam Normal complete blood count and differential obtained within 60 days prior to immunization, and defined as: hemoglobin greater than or equal to 12.0 gm/dl for females and greater than or equal to 14.0 gm/dl for males white blood cell count greater than or equal to 3500 cells/mm3 platelet count between 150,000 and 550,000 cells/mm3 CD4+ T cell count greater than or equal to 400 cells/mm3 (if a single CD4+ T cell count <400 cells/mm3 is obtained, a repeat count will be performed and immunization will proceed if the repeat count is greater than or equal to 400 cells/mm3) Anti-nuclear antibody titer <1:80 (by IFA) and negative anti-DNA antibody within 60 days prior to immunization Negative for Hepatitis B surface antigen and Hepatitis C AST and ALT within normal institutional limits obtained within 60 days prior to immunization Serum creatinine, Na+, K+ and Cl- within normal institutional limits, obtained within 60 days prior to immunization Serum creatine phosphokinase (CPK) within normal institutional limits obtained within 60 days prior to immunization Not planning to become pregnant during study vaccinations and for three months after last vaccination Availability for at least one year of follow-up Exclusion Criteria: History of immunosuppressive illness, chronic illness (e.g. asthma, diabetes, hypertension, bleeding diathesis, etc), or Receiving therapy or prophylaxis for tuberculosis Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol. Specifically excluded are persons with a history of suicide attempts, recent suicidal ideation or who have past or present psychosis Live attenuated vaccines within 60 days of study enrollment (Note: subunit or killed vaccines [e.g. influenza or pneumococcal] are not exclusionary, but should be given at least 2 weeks before or after HIV immunization) Use of experimental agents within 30 days prior to study enrollment Receipt of blood products or immunoglobulin in the past 6 months Subjects with known allergy to the antibiotic kanamycin Pregnancy at the time of vaccination (urine pregnancy test) Nursing mother at the time of vaccination Any member of the Investigator's laboratory program Participation in previous HIV vaccine trial